UBS Group’s XORTX Therapeutics XRTX Stock Holding History

UBS Group’s Portfolio XRTX Stock Details XRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-280	Closed	-$787	–	11260
2025 Q4	$787	Buy	280 +233	+496%	+$773	﹤0.01%	9810
2025 Q3	$190	Sell	47 -4,111	-99%	-$17.2K	﹤0.01%	9828
2025 Q2	$18.8K	Buy	+4,158	New	+$19.6K	﹤0.01%	8486
2025 Q1	–	Sell	-3,486	Closed	-$19.7K	–	10775
2024 Q4	$19.7K	Sell	3,486 -270	-7%	-$1.86K	﹤0.01%	7880
2024 Q3	$30.8K	Buy	+3,756	New	+$32.1K	﹤0.01%	7116
2023 Q1	–	Hold	0	–	-$53	–	10491
2022 Q4	–	Hold	0	–	–	–	10473
2022 Q3	–	Sell	-14	Closed	-$8K	–	11009
2022 Q2	$8K	Buy	14 +5	+56%	+$3.17K	﹤0.01%	8363
2022 Q1	$7K	Buy	9 +6	+200%	+$3.96K	﹤0.01%	8852
2021 Q4	$2K	Buy	+3	New	+$3.09K	﹤0.01%	9842

Other funds holding XRTX

KWM

Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS Group's XRTX Position: Q1 2026 in Review

UBS Group sold out of XORTX Therapeutics (XRTX) in Q1 2026, closing a stake of 280 shares — an estimated $787 sold.

UBS Group first reported a position in XRTX in Q4 2021 and held it in 8 quarters. The position peaked at $30.8K in Q3 2024. 3 funds tracked by Wall St. Rank hold XRTX as of Q1 2026.

UBS Group reported no remaining XORTX Therapeutics position as of Q1 2026 after selling out during the quarter.
UBS Group sold 280 XORTX Therapeutics shares in Q1 2026, an estimated $787.
UBS Group first reported a position in XORTX Therapeutics in Q4 2021 and held it in 8 quarters.
UBS Group's XORTX Therapeutics position peaked at $30.8K in Q3 2024.
3 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.